January 6, 2014
Genzyme Corporation has presented the International Rare Disease Research Consortium (IRDiRC) Executive Committee with a letter of intent to support the IRDiRC objectives by being a part of the consortium. It is now officially a new member of IRDiRC. Genzyme, a Sanofi company, was willing to join the IRDiRC collaborative effort in order to support the objectives of financing research for the treatment of rare diseases with an anticipated budget aligned with the IRDiRC scientific objectives, funding level, policies and governance structure. Genzyme has nominated Dr Carlo Incerti, SVP, Head of Global Medical Affairs to represent Genzyme on the IRDiRC Executive Committee and Seng Cheng, PhD Group Vice President, Genetic Diseases Science, to be a member of one of the Scientific Committees.